PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 21, 2026Communications Medicine0 citationsOpen Access

Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragments

MTMamoru TakadaChiba UniversitySGSakuntha GunarathnaUniversity of North DakotaRNRegina NguyenUniversity of North Dakota

Key Points

  • This research aims to understand how abemaciclib works in treating metastatic breast cancer using cfDNA profiling.
  • Analyzed circulating chromatin fragments in patients undergoing treatment with abemaciclib.
  • Profiling cfDNA to assess molecular changes linked to therapy response.
  • Evaluated the potential of cfDNA as a biomarker for treatment monitoring.
  • cfDNA profiling reflects changes in response to targeted therapy.
  • Identified molecular markers that predict therapeutic outcomes.
  • Demonstrated the feasibility of using cfDNA in clinical practice for monitoring.

Abstract

Our findings suggest that cfDNA profiling captures molecular changes induced by targeted therapy and may serve as a practical biomarker for treatment monitoring and prediction of therapeutic response. This research provides insight into the mechanisms of CDK4/6 inhibitor action in metastatic breast cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Takada et al. (2026) studied this question.

synapsesocial.com/papers/69be35166e48c4981c67330fhttps://doi.org/10.1038/s43856-026-01494-w
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 1074: Pre-treatment circulating tumor cells are a significant predictor of progression in patients with metastatic breast cancer undergoing abemaciclib therapy2026
  2. 2Abstract 5266: Deciphering the systemic immune effects of abemaciclib in recurrent metastatic breast cancer: A multicenter, prospective study2024
  3. 3Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy2026 · 1 citations
  4. 4Clinical use of Abemaciclib a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with breast cancer — literature review2024
  5. 5Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated <scp>CDK4</scp> /6 Pathway2026